Xeris Biopharma (XERS) Stock Price & Analysis
Score
AI Analysis
SnapshotXeris Biopharma Holdings is a growth-led story right now — Growth 94/100 is the pillar doing the heavy lifting (overall 65/100) in Biotechnology. Under the hood: revenue compounding ~39% annually over recent years. Street targets still imply ~12% below the current price.
Price History
Price: —
Fair value: —
—
P/E (TTM): —
Net Income (TTM): —
Score: —
—
Score Breakdown
Market percentile scores loading…
Value
Growth
Quality
Financial Summary
Xeris Biopharma Holdings, Inc. (XERS) last printed $16.97. Equity value is $3.10B. Trailing earnings multiple —. The revenue row is reported history. Targets and ratings are on the forecast page.
Financials
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| $1.07M | $1.56M | $2.46M | $2.72M | $20.43M | $49.59M | $110.25M | $163.91M | $203.07M | $291.85M |
About
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.